Metropolitan Life Insurance Company (MetLife)’s Pacira BioSciences PCRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,422	Closed	-$70.8K	–	1520
2024 Q1	$70.8K	Sell	2,422 -247	-9%	-$7.59K	﹤0.01%	1234
2023 Q4	$90.1K	Hold	2,669	–	–	﹤0.01%	1144
2023 Q3	$81.9K	Buy	2,669 +180	+7%	+$6.49K	﹤0.01%	1125
2023 Q2	$99.7K	Buy	2,489 +84	+3%	+$3.47K	﹤0.01%	1018
2023 Q1	$98.1K	Sell	2,405 -373	-13%	-$14.8K	0.01%	1002
2022 Q4	$107K	Buy	2,778 +97	+4%	+$4.72K	﹤0.01%	1015
2022 Q3	$143K	Hold	2,681	–	–	0.01%	821
2022 Q2	$156K	Hold	2,681	–	–	0.01%	827
2022 Q1	$205K	Sell	2,681 -9,225	-77%	-$615K	0.01%	803
2021 Q4	$716K	Hold	11,906	–	–	0.01%	1189
2021 Q3	$667K	Hold	11,906	–	–	0.01%	1254
2021 Q2	$722K	Buy	11,906 +789	+7%	+$49.9K	0.01%	1257
2021 Q1	$779K	Sell	11,117 -1,561	-12%	-$112K	0.01%	1129
2020 Q4	$759K	Hold	12,678	–	–	0.01%	1083
2020 Q3	$762K	Hold	12,678	–	–	0.01%	907
2020 Q2	$665K	Sell	12,678 -264	-2%	-$11K	0.01%	1015
2020 Q1	$434K	Hold	12,942	–	–	0.01%	1135
2019 Q4	$586K	Sell	12,942 -405	-3%	-$17.2K	0.01%	1226
2019 Q3	$508K	Hold	13,347	–	–	0.01%	1285
2019 Q2	$580K	Hold	13,347	–	–	0.01%	1218
2019 Q1	$508K	Hold	13,347	–	–	0.01%	1287
2018 Q4	$574K	Buy	13,347 +375	+3%	+$17.5K	0.01%	1105
2018 Q3	$638K	Hold	12,972	–	–	0.01%	1201
2018 Q2	$416K	Hold	12,972	–	–	0.01%	1446
2018 Q1	$404K	Hold	12,972	–	–	0.01%	1417
2017 Q4	$592K	Sell	12,972 -13,709	-51%	-$543K	0.01%	1168
2017 Q3	$1M	Hold	26,681	–	–	0.01%	1248
2017 Q2	$1.27M	Buy	26,681 +1,796	+7%	+$83.3K	0.01%	1114
2017 Q1	$1.14M	Sell	24,885 -976	-4%	-$42.2K	0.01%	1169
2016 Q4	$835K	Hold	25,861	–	–	0.01%	1400
2016 Q3	$885K	Hold	25,861	–	–	0.01%	1352
2016 Q2	$872K	Hold	25,861	–	–	0.01%	1334
2016 Q1	$1.37M	Buy	25,861 +207	+0.8%	+$12.1K	0.01%	1029
2015 Q4	$1.97M	Sell	25,654 -184	-0.7%	-$10.4K	0.02%	901
2015 Q3	$1.06M	Sell	25,838 -260	-1%	-$15.9K	0.01%	1159
2015 Q2	$1.85M	Sell	26,098 -1,283	-5%	-$101K	0.01%	996
2015 Q1	$2.43M	Sell	27,381 -40	-0.1%	-$4.06K	0.02%	831
2014 Q4	$2.43M	Hold	27,421	–	–	0.02%	887
2014 Q3	$2.66M	Hold	27,421	–	–	0.02%	823
2014 Q2	$2.52M	Buy	27,421 +5,107	+23%	+$389K	0.02%	894
2014 Q1	$1.56M	Hold	22,314	–	–	0.01%	1094
2013 Q4	$1.28M	Hold	22,314	–	–	0.01%	1190
2013 Q3	$1.07M	Hold	22,314	–	–	0.01%	1237
2013 Q2	$647K	Buy	+22,314	New	+$646K	0.01%	1524

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PCRX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 2,422 shares — an estimated $70.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PCRX in Q2 2013 and held it in 44 quarters. The position peaked at $2.66M in Q3 2014. 281 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,422 Pacira BioSciences shares in Q2 2024, an estimated $70.8K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Pacira BioSciences in Q2 2013 and held it in 44 quarters.
Metropolitan Life Insurance Company (MetLife)'s Pacira BioSciences position peaked at $2.66M in Q3 2014.
281 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.